"Study of LX4211 in subjects with type 2 diabetes mellitus (NCT00962065)", , 14 September 2009 (2009-09-14), XP002632802, Retrieved from the Internet: URL:https://integrity.thomson-pharma.com/i ntegrity/xmlxsl/pk_ref_list.xml_related_re f_to?p_id=636286&p_origen=PRO&p_tsearch=li nk [retrieved on 2011-04-14] (B1)

"Study of LX4211 in subjects with type 2 diabetes mellitus", , 4 February 2011 (2011-02-04), XP002632803, Retrieved from the Internet: URL:http://clinicaltrials.gov/ct2/show/res ults/NCT00962065?sect=X0125all [retrieved on 2011-04-14] (B1)

FREIMAN J ET AL: "LX4211, a dual SGLT2/SGLT1 inhibitor, shows rapid and significant improvement in glycemic control over 28 days in patients with type 2 diabetes (T2DM)", DIABETES, AMERICAN DIABETES ASSOCIATION, US, vol. 59, no. suppl. 1, 25 June 2010 (2010-06-25), pages LB5-LB6, XP009146827, ISSN: 0012-1797 (B1)

Freiman et al.: "LX4211, an SGLT2 Inhibitor, Shows Improvements in Cardiovascular Risk Factors over 4 Weeks in Patients with Type 2 Diabetes Mellitus.", , 21 June 2010 (2010-06-21), XP002632760, Retrieved from the Internet: URL:http://www.posters2view.com/endo/ [retrieved on 2011-04-04] (B1)

Freiman et al.: "LX4211, an SGLT2 Inhibitor, Shows Rapid and Significant Improvement in Glycemic Control over 4 Weeks inPatients with Type 2 Diabetes Mellitus.", , 22 June 2010 (2010-06-22), XP002632759, Retrieved from the Internet: URL:http://www.endojournals.org/abstracts/ abstracts.dtl [retrieved on 2011-04-04] (B1)

WO-A2-2008/042688 (B1)

KOMOROSKI B ET AL: "Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.", CLINICAL PHARMACOLOGY AND THERAPEUTICS MAY 2009 LNKD- PUBMED:19129749, vol. 85, no. 5, May 2009 (2009-05), pages 513-519, XP009146835, ISSN: 1532-6535 (B1)

Lexicon Pharmaceuticals INc: "Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients", , 20 January 2010 (2010-01-20), XP002632758, Retrieved from the Internet: URL:http://www.news-medical.net/news/20100 120/Lexicon-Pharmaceuticals-reports-positi ve-results-from-its-LX4211-Phase-2-trial-i n-type-2-diabetic-patients.aspx [retrieved on 2011-04-04] (B1)

Lexicon Pharmaceuticals: "LX4211", , 4 April 2011 (2011-04-04), XP002632761, Retrieved from the Internet: URL:http://www.lexicon-genetics.com/pipeli ne/lx4211.html [retrieved on 2011-04-04] (B1)

WASHBURN WILLIAM N: "Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 19, no. 11, 1 November 2009 (2009-11-01), pages 1485-1499, XP002593697, ISSN: 1354-3776, DOI: DOI:10.1517/13543770903337828 (B1)

WO-A1-2010/009197 (B1)

John Doupis ET AL: "DPP4 Inhibitors: a new approach in diabetes treatment", Advances in Therapy, vol. 25, no. 7, 1 July 2008 (2008-07-01), pages 627-643, XP55071538, ISSN: 0741-238X, DOI: 10.1007/s12325-008-0076-1 (B1)